Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor

References

• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–38.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx. 2004;1:273–83.
   PubMedGoogle Scholar
• Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87:617–24.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Montes J, Doorish C, Albert SM, Mitsumoto H. Outcome measures for early phase clinical trials. Amyotroph Lateral Scler. 2007;8:270–3.
   PubMed Web of Science ®Google Scholar
• Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, et al. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012;45:81–5.
   PubMed Web of Science ®Google Scholar
• Rutkove SB. Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:384–93
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Franchignoni F, Mora G, Giordano A, Volanti P, Chio A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84:1340–5.
   PubMed Web of Science ®Google Scholar
• Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase I trial outcomes. Ann Neurol. 2014;75:363–73.
   PubMed Web of Science ®Google Scholar
• Han JJ, de Bie E, Nicorici A, Abresch RT, Bajcsy R, Kurillo G. Reachable workspace reflects dynamometer-measured upper extremity strength in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2015;52:948–55.
   PubMed Web of Science ®Google Scholar
• Han JJ, Kurillo G, Abresch RT, de Bie E, Nicorici A, Bajcsy R. Upper extremity three-dimensional reachable workspace analysis in dystrophinopathy using Kinect. Muscle Nerve. 2015;52:344–55.
   PubMed Web of Science ®Google Scholar
• Han JJ, Kurillo G, Abresch RT, de Bie E, Nicorici A, Bajcsy R. Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect. Muscle Nerve. 2015;51:168–75.
   PubMed Web of Science ®Google Scholar
• Han JJ, Kurillo G, Abresch RT, Nicorici A, Bajcsy R. Validity, reliability, and sensitivity of a 3D vision sensor-based upper extremity reachable workspace evaluation in neuromuscular diseases. PLoS Curr. 2013;5.
   Google Scholar
• Kurillo G, Chen A, Bajcsy R, Han JJ. Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care. 2013;21:641–56.
   PubMed Web of Science ®Google Scholar
• Kurillo G, Han JJ, Nicorici A, Bajcsy R. Tele-MFAsT: kinect-based tele-medicine tool for remote motion and function assessment. Stud Health Technol Inform. 2014;196:215–21.
   PubMedGoogle Scholar
• Oskarsson B, Joyce NC, De Bie E, Nicorici A, Bajcsy R, Kurillo G, et al. Upper extremity three-dimensional reachable workspace assessment in amyotrophic lateral sclerosis by Kinect sensor. Muscle Nerve. 2016;53:234–41.
   PubMed Web of Science ®Google Scholar
• Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4:186–97.
   PubMed Web of Science ®Google Scholar
• Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009;10:324–31.
   PubMed Web of Science ®Google Scholar
• Han JJ, de Bie E, Nicorici A, Abresch RT, Anthonisen C, Bajcsy R, et al. Reachable workspace and performance of upper limb (PUL) in Duchenne muscular dystrophy. Muscle Nerve. 2016;53:545–54.
   PubMed Web of Science ®Google Scholar
• Kurillo G, Han JJ, Obdrzalek S, Yan P, Abresch RT, Nicorici A, et al. Upper extremity reachable workspace evaluation with Kinect. Stud Health Technol Inform. 2013;184:247–53.
   PubMedGoogle Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardization of spirometry. Eur Respir J. 2005;26:319–38.
   PubMed Web of Science ®Google Scholar
• Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat. 1998;24:323–55.
   Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014;49:441–325.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011;77:235–41.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Wicks P, Heywood J, Kasarskis E. Modifiable barriers to enrollment in American ALS research studies. Amyotroph Lateral Scler. 2010;11:502–7.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
   PubMed Web of Science ®Google Scholar
• Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration. Chest. 1993;103:508–13.
   PubMed Web of Science ®Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   PubMed Web of Science ®Google Scholar